NCT07041437View on ClinicalTrials.gov

Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

January 31, 2027

Conditions

Advanced Breast Cancer

Interventions

DRUG

SHR-A2102

ADC

DRUG

Adebrelimab

PD-L1 inhibitor

Trial Locations (1)

200230

Fudan Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER